Safety of anidulafungin in solid organ transplant recipients
J.M. Aguado, E. Varo, P. Usetti, J.C. Pozo, A. Moreno, M. Catalán, O. Len, M. Blanes, A. Solé, P. Muñoz, M. Montejo, the TOSCANA Study Group – 12 February 2012 – The aim of this study was the evaluation of the safety of anidulafungin in adult solid organ transplantation (SOT) recipients. During the study period (14 months), we included all consecutive SOT recipients from 14 centers who received anidulafungin for at least 48 hours for the treatment of invasive fungal infections (IFIs) or as prophylaxis. Relevant clinical and analytical information on clinical charts was reviewed.